Answers In CME

•

Kênh • 6 chương trình

Khoa học đời sống

Khoa học đời sống

Hằng tuần
Khoa học đời sống

Khoa học đời sống

Hằng tuần
Khoa học đời sống

Khoa học đời sống

Hằng tuần
Khoa học đời sống

Khoa học đời sống

Hằng tuần
Khoa học đời sống

Khoa học đời sống

Hằng tuần
Khoa học đời sống

Khoa học đời sống

Hằng tuần

4 NGÀY TRƯỚC

Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers

Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.

4 ngày trước

•

14 phút
29 THG 11

Erin Barrett (Wei), MD - Focusing on the Patient to Enhance Therapeutic Care: Advancing Early Diagnosis and Management of Bullous Pemphigoid

Please visit answersincme.com/ZPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatologic diseases discusses the diagnosis and treatment of bullous pemphigoid. Upon completion of this activity, participants should be better able to: Review the clinical impact of bullous pemphigoid (BP) on patients; Outline diagnostic approaches to enhance the timely identification of patients with BP; and Identify clinical advances that may evolve the therapeutic paradigm for patients with BP.

29 thg 11

•

15 phút
13 THG 12

Alexander I. Spira, MD, PhD, FACP - Biomarkers at the Forefront: The Crucial Role of Testing Across Solid Tumor Types

Please visit answersincme.com/SWT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the importance of biomarker testing in solid tumors. Upon completion of this activity, participants should be better able to: Recognize the impact of biomarker testing on patient outcomes across tumor types; Identify optimal strategies for implementing biomarker testing in clinical practice; and Outline patient-centered strategies to optimize outcomes following identification of actionable biomarkers/mutations.

13 thg 12

•

15 phút
4 NGÀY TRƯỚC

Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers

Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.

4 ngày trước

•

14 phút
06/10/2023

Shawn Kwatra, MD - Itching for Relief: Exploring the Role of Novel Biologics in Prurigo Nodularis

Please visit answersincme.com/SRG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the diagnosis and treatment of prurigo nodularis. Upon completion of this activity, participants should be better able to: Recognize the need for treatment intensification in patients with prurigo nodularis (PN), including patients of color, using novel biologic therapies; Review the clinical profiles of novel biologic therapies for PN; and Outline clinical factors that may facilitate the optimal use of biologic therapies in patients with PN.

06/10/2023

•

17 phút
12 THG 12

Stella Lee, MD - Biologic Therapies for Chronic Rhinosinusitis With Nasal Polyps: Practical, Patient-Centered Perspectives for Providers

Please visit answersincme.com/YWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rhinology discusses the use of biologics for the management of chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Identify key considerations for initiating a biologic therapy in patients with CRSwNP; Discuss the clinical impact of the latest data for novel approved biologics in CRSwNP; and Apply best practice approaches for management of biologics in patients with CRSwNP. This activity is intended for US healthcare professionals only.

12 thg 12

•

19 phút
29 THG 11

Csaba P. Kovesdy, MD - Integrating Nonsteroidal MRAs in Practice: A Guideline-Driven Approach to the Management of CKD and T2D

Please visit answersincme.com/YTP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cardiology and nephrology discuss the latest evidence and guidance on the use of nonsteroidal mineralocorticoid receptor antagonist (MRA) for the treatment of cardio-renal-metabolic conditions. Upon completion of this activity, participants should be better able to: Identify patients with type 2 diabetes (T2D) who are at high risk for chronic kidney disease (CKD) progression and cardiovascular events; Outline the clinical implications of updated CKD guidelines regarding the use of nonsteroidal MRA therapy in patients with T2D and CKD; and Describe the latest evidence on the use of nonsteroidal MRA therapies in individuals with cardio-renal-metabolic conditions.

29 thg 11

•

16 phút
1 NGÀY TRƯỚC

Claus Bachert, MD, PhD / Cecelia Damask, DO - Managing CRSwNP With Biologic Therapies: A Global Dialogue

Please visit answersincme.com/KSU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in otolaryngology discuss the role of biologic therapies in chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Recognize considerations for initiating treatment with a biologic therapy in patients with CRSwNP; Review the clinical implications of the latest efficacy and safety data for novel approved biologics in CRSwNP; and Outline strategies to optimize the use of biologics in patients with CRSwNP over the long term.

1 ngày trước

•

19 phút
4 NGÀY TRƯỚC

Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers

Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.

4 ngày trước

•

14 phút
2 THG 12

Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Advancing Care in EGFR-Mutated NSCLC: Unveiling New Horizons With ADCs

Please visit answersincme.com/860/93496951-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective on the treatment journey. Upon completion of this activity, participants should be better able to: Identify when perioperative immunotherapeutic approaches should be considered for patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.

2 thg 12

•

33 phút

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for busy healthcare professionals to cover the diagnosis, treatment, followup, and clinical management of various medical conditions. Earning your CME/CE credit has never been faster or easier.